Published in Histol Histopathol on January 01, 1997
Autophagy as a regulated pathway of cellular degradation. Science (2000) 17.27
Autophagy in cell death: an innocent convict? J Clin Invest (2005) 10.70
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev (2007) 7.41
Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol (2008) 6.78
Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A (2006) 4.81
Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci (2008) 4.63
Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci U S A (2007) 3.92
Convergence of multiple autophagy and cytoplasm to vacuole targeting components to a perivacuolar membrane compartment prior to de novo vesicle formation. J Biol Chem (2001) 3.90
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J (2012) 3.37
DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol (2002) 3.32
Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol (2007) 3.29
The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A (2001) 3.16
Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol (2005) 2.56
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci U S A (2004) 2.56
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem (2008) 2.30
Autophagy and p62 in cardiac proteinopathy. Circ Res (2011) 2.24
Autophagic stress in neuronal injury and disease. J Neuropathol Exp Neurol (2006) 2.17
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
Autophagy failure in Alzheimer's disease--locating the primary defect. Neurobiol Dis (2011) 2.14
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci (2013) 1.88
Autophagy in yeast: mechanistic insights and physiological function. Microbiol Mol Biol Rev (2001) 1.78
Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol (2003) 1.75
Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta (2008) 1.73
Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev (2007) 1.72
Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet (2011) 1.68
Autophagic dysfunction in mucolipidosis type IV patients. Hum Mol Genet (2008) 1.66
All-you-can-eat: autophagy in neurodegeneration and neuroprotection. Mol Neurodegener (2009) 1.60
The crosstalk between autophagy and apoptosis: where does this lead? Protein Cell (2012) 1.60
Epigallocatechin-3-gallate attenuates impairment of learning and memory in chronic unpredictable mild stress-treated rats by restoring hippocampal autophagic flux. PLoS One (2014) 1.47
Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain. Am J Pathol (2007) 1.46
The neurology of mTOR. Neuron (2014) 1.43
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis (2009) 1.43
S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res (2009) 1.42
Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J Cell Biol (2004) 1.39
Atg23 is essential for the cytoplasm to vacuole targeting pathway and efficient autophagy but not pexophagy. J Biol Chem (2003) 1.39
RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci (2008) 1.37
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Autophagy in neurite injury and neurodegeneration: in vitro and in vivo models. Methods Enzymol (2009) 1.36
Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem (2011) 1.33
Autophagy in neuroprotection and neurodegeneration: A question of balance. Future Neurol (2008) 1.31
Neuronal autophagy and neurodegenerative diseases. Exp Mol Med (2012) 1.28
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med (2008) 1.24
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna) (2010) 1.22
The p75 neurotrophin receptor can induce autophagy and death of cerebellar Purkinje neurons. J Neurosci (2004) 1.21
TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells. J Biol Chem (2004) 1.18
Up-regulation of transient receptor potential canonical 1 (TRPC1) following sarco(endo)plasmic reticulum Ca2+ ATPase 2 gene silencing promotes cell survival: a potential role for TRPC1 in Darier's disease. Mol Biol Cell (2006) 1.17
Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev (2014) 1.17
Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol (2006) 1.17
Systems biology of the autophagy-lysosomal pathway. Autophagy (2011) 1.15
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. Pharmaceuticals (Basel) (2010) 1.13
The mitochondrial permeability transition pore regulates nitric oxide-mediated apoptosis of neurons induced by target deprivation. J Neurosci (2011) 1.13
Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol (2009) 1.11
An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.11
Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegener (2012) 1.10
Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.09
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr (2011) 1.08
Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol (2012) 1.08
Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol (2012) 1.07
Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. J Neurochem (2010) 1.07
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
Autophagy and Mitophagy in Cellular Damage Control. Redox Biol (2013) 1.04
Programmed cell death in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.04
Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol (2009) 1.04
Autophagic/lysosomal dysfunction in Alzheimer's disease. Alzheimers Res Ther (2013) 1.01
Vanadium induces dopaminergic neurotoxicity via protein kinase Cdelta dependent oxidative signaling mechanisms: relevance to etiopathogenesis of Parkinson's disease. Toxicol Appl Pharmacol (2009) 1.01
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener (2010) 1.00
Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy (2012) 1.00
Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. Parkinsons Dis (2011) 0.99
Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res (2011) 0.99
The emerging role of autophagy in Parkinson's disease. Mol Brain (2009) 0.97
Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci (2012) 0.97
Neuronal autophagy: going the distance to the axon. Autophagy (2007) 0.97
Insulin-like growth factor-I prevents the accumulation of autophagic vesicles and cell death in Purkinje neurons by increasing the rate of autophagosome-to-lysosome fusion and degradation. J Biol Chem (2009) 0.96
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy (2014) 0.96
Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res (2010) 0.96
Cdk5 activity in the brain - multiple paths of regulation. J Cell Sci (2014) 0.95
dnc-1/dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. PLoS One (2013) 0.94
The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol (2016) 0.93
Sex-specific hippocampus-dependent cognitive deficits and increased neuronal autophagy in DEspR haploinsufficiency in mice. Physiol Genomics (2008) 0.92
Interplay between the ubiquitin-proteasome system and autophagy in proteinopathies. Int J Physiol Pathophysiol Pharmacol (2009) 0.92
Allopregnanolone treatment delays cholesterol accumulation and reduces autophagic/lysosomal dysfunction and inflammation in Npc1-/- mouse brain. Brain Res (2009) 0.92
Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int J Mol Sci (2014) 0.92
Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal (2011) 0.92
Alterations in ROS activity and lysosomal pH account for distinct patterns of macroautophagy in LINCL and JNCL fibroblasts. PLoS One (2013) 0.92
Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci U S A (1999) 0.92
Autophagy in neurodegenerative diseases: from mechanism to therapeutic approach. Mol Cells (2015) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum Mol Genet (2012) 0.91
Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci (2008) 0.91
Diversity in the regulation of autophagy and mitophagy: lessons from Parkinson's disease. Parkinsons Dis (2011) 0.90
Impairment of Atg5-dependent autophagic flux promotes paraquat- and MPP⁺-induced apoptosis but not rotenone or 6-hydroxydopamine toxicity. Toxicol Sci (2013) 0.90
Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ (2012) 0.90
Teaching the basics of autophagy and mitophagy to redox biologists--mechanisms and experimental approaches. Redox Biol (2015) 0.90
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry (2001) 3.47
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
A new Micromonospora-produced macrolide antibiotic, rosamicin. J Antibiot (Tokyo) (1972) 3.12
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Structure of Thermotoga maritima stationary phase survival protein SurE: a novel acid phosphatase. Structure (2001) 2.43
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
Neuroinflammatory processes in Parkinson's disease. Ann Neurol (2003) 2.10
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Facial nuclear degeneration on MRI in bulbar onset amyotrophic lateral sclerosis. QJM (2013) 2.01
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain (1999) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology (1998) 1.96
The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci (2003) 1.94
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics. Nature (1987) 1.91
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 1.85
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Eye movements in parkinsonian syndromes. Ann Neurol (1994) 1.84
Cortical control of reflexive visually-guided saccades. Brain (1991) 1.84
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol (1996) 1.77
A third locus for autosomal dominant cerebellar ataxia type I maps to chromosome 14q24.3-qter: evidence for the existence of a fourth locus. Am J Hum Genet (1994) 1.76
A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology (1987) 1.70
Pallidal stimulation for Parkinson's disease. Two targets? Neurology (1997) 1.69
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res (1983) 1.67
Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ (2006) 1.65
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet (1998) 1.64
Color Doppler imaging of the uterine artery in pregnancy: normal ranges of impedance to blood flow, mean velocity and volume of flow. Ultrasound Obstet Gynecol (1992) 1.63
Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A (1987) 1.62
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem (2002) 1.61
The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease. Mov Disord (1993) 1.60
Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry (2005) 1.60
Confirmation of linkage of Friedreich ataxia to chromosome 9 and identification of a new closely linked marker. Genomics (1989) 1.59
Entorhinal cortex of the rat: cytoarchitectonic subdivisions and the origin and distribution of cortical efferents. Hippocampus (1997) 1.58
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol (1978) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol (1999) 1.57
Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet (1998) 1.56
Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis. Mov Disord (1989) 1.55
Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD. Neurology (2000) 1.55
Improved outcomes in the management of high-risk incisional hernias utilizing biological mesh and soft-tissue reconstruction: a single center experience. World J Surg (2014) 1.49
Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p. Hum Mol Genet (1994) 1.49
Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). Neurology (2002) 1.48